CD8A and neoplasm: Since CY treatment is associated with an IFN-α/β response and because primary CD8 T cell responses to apoptotic cells and cross-presented antigens are type-I IFN-dependent [8], [30], we hypothesized that the type-I IFN response could be responsible for priming the anti-tumor CD8 T cell response.